IL33 and rheumatoid arthritis: Conversely, HIF-1α can reduce ILC2 responsiveness to IL-33 and even further exacerbate IL-33 production in rheumatoid arthritis, making it a target of drug treatment and indicating that this proinflammatory-hypoxic crosstalk is bidirectional [286,287].